Biology:Biostrophin
From HandWiki
Revision as of 00:13, 11 August 2021 by imported>Rjetedi (fix)
Biostrophin is a drug which may serve as a vehicle for gene therapy, in the treatment of Duchenne and Becker muscular dystrophy.[1]
As mutations in the gene which codes for the protein dystrophin is the underlying defect responsible for both disorders, biostrophin will deliver a genetically-engineered, functional copy of the gene at the molecular level to affected muscle cells.[1] Dosage, as well as a viable means for systemic release of the drug in patients, is currently being investigated with the use of both canine and primate animal models.[2]
Biostrophin is being manufactured by Asklepios BioPharmaceuticals, Inc., with funding provided by the Muscular Dystrophy Association.[3]
See also
Other drugs for Duchenne muscular dystrophy
- Ataluren
- Rimeporide (experimental)
References
- ↑ 1.0 1.1 "Chronicles in drug discovery". Drug News & Perspectives 18 (8): 517–522. Oct 2005. doi:10.1358/dnp.2005.18.8.953409. ISSN 0214-0934. PMID 16391721.
- ↑ http://www.ncbiotech.org/news_and_events/industry_news/duchenne.html Dec 2006
- ↑ "Asklepios Biopharmaceutical, Inc. Announces Cross License with GlaxoSmithKline". 2006-09-28. http://www.businesswire.com/news/home/20060928005134/en/Asklepios-Biopharmaceutical-Announces-Cross-License-GlaxoSmithKline.
External links
 |  |
